Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCFinancial_Report.xls
10-K - FORM 10-K - KERYX BIOPHARMACEUTICALS INCv302731_10k.htm
EX-31.2 - EXHIBIT 31.2 - KERYX BIOPHARMACEUTICALS INCv302731_ex31-2.htm
EX-21.1 - EXHIBIT 21.1 - KERYX BIOPHARMACEUTICALS INCv302731_ex21-1.htm
EX-31.1 - EXHIBIT 31.1 - KERYX BIOPHARMACEUTICALS INCv302731_ex31-1.htm
EX-32.2 - EXHIBIT 32.2 - KERYX BIOPHARMACEUTICALS INCv302731_ex32-2.htm
EX-23.1 - EXHIBIT 23.1 - KERYX BIOPHARMACEUTICALS INCv302731_ex23-1.htm
EX-10.20 - EXHIBIT 10.20 - KERYX BIOPHARMACEUTICALS INCv302731_ex10-20.htm

 

Exhibit 32.1

 

STATEMENT OF CHIEF EXECUTIVE OFFICER OF
KERYX BIOPHARMACEUTICALS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of Keryx Biopharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2011 as filed with the Securities and Exchange Commission (the “Report”), I, Ron Bentsur, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

 

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 2, 2012 /s/ Ron Bentsur  
  Ron Bentsur  
  Chief Executive Officer  
  Principal Executive Officer